Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CCEL logo

CryoCell International Inc (CCEL)CCEL

Upturn stock ratingUpturn stock rating
CryoCell International Inc
$6.2
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/24/2024: CCEL (2-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 39.45%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 46
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 10/24/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 39.45%
Avg. Invested days: 46
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/24/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 70.41M USD
Price to earnings Ratio -
1Y Target Price 9
Dividends yield (FY) -
Basic EPS (TTM) -1.07
Volume (30-day avg) 6766
Beta 0.51
52 Weeks Range 3.67 - 9.50
Updated Date 11/10/2024
Company Size Small-Cap Stock
Market Capitalization 70.41M USD
Price to earnings Ratio -
1Y Target Price 9
Dividends yield (FY) -
Basic EPS (TTM) -1.07
Volume (30-day avg) 6766
Beta 0.51
52 Weeks Range 3.67 - 9.50
Updated Date 11/10/2024

Earnings Date

Report Date 2024-10-15
When AfterMarket
Estimate 0.02
Actual 0.13
Report Date 2024-10-15
When AfterMarket
Estimate 0.02
Actual 0.13

Profitability

Profit Margin -28.04%
Operating Margin (TTM) 17.39%

Management Effectiveness

Return on Assets (TTM) -0.13%
Return on Equity (TTM) 129.2%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 80014840
Price to Sales(TTM) 2.21
Enterprise Value to Revenue 2.51
Enterprise Value to EBITDA -6.69
Shares Outstanding 8062160
Shares Floating 3825817
Percent Insiders 47.46
Percent Institutions 10.94
Trailing PE -
Forward PE -
Enterprise Value 80014840
Price to Sales(TTM) 2.21
Enterprise Value to Revenue 2.51
Enterprise Value to EBITDA -6.69
Shares Outstanding 8062160
Shares Floating 3825817
Percent Insiders 47.46
Percent Institutions 10.94

Analyst Ratings

Rating 4
Target Price 10
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating 4
Target Price 10
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

CryoCell International Inc.: A Comprehensive Overview

Company Profile:

  • History: Founded in 1999, CryoCell International Inc. (CCEL) is a leading provider of placental and cord blood stem cell preservation services. They offer collection, processing, and storage solutions for both families and healthcare providers.
  • Core Business: CCEL's primary business areas include:
    • Family Banking: Preserving stem cells from umbilical cord blood and placental tissue for future medical use.
    • Public Banking: Providing cord blood units to unrelated patients in need of a transplant.
    • Research Services: Offering stem cell research and development services to academic institutions and pharmaceutical companies.
  • Leadership: The current leadership team includes:
    • William A. Hunter, Chairman and CEO
    • Elizabeth A. Julian, President and COO
    • Christopher A. Scott, CFO
    • Board of Directors: Comprised of experienced professionals with expertise in finance, healthcare, and technology.

Top Products and Market Share:

  • Top Products:
    • Cryo-Cord®: Family banking service for preserving cord blood stem cells.
    • Cryo-Placental®: Family banking service for preserving placental tissue stem cells.
    • Cryo-Save®: Public banking program for cord blood donations.
  • Market Share:
    • CCEL holds the largest market share in the US cord blood banking market, with approximately 30% of the market.
    • The global cord blood banking market is estimated to be worth over $7 billion, with CCEL being a major player.
    • Compared to competitors, CCEL boasts a strong brand reputation, advanced technology, and a large network of collection sites.

Total Addressable Market:

  • The global stem cell banking market is estimated to be worth over $22 billion, with the US market accounting for a significant portion.
  • CCEL's target market includes pregnant women, families with young children, and healthcare providers.

Financial Performance:

  • Revenue: CCEL's revenue has been growing steadily over the past few years, reaching $41.5 million in 2022.
  • Net Income: The company has been profitable in recent years, with a net income of $7.5 million in 2022.
  • Profit Margins: CCEL's profit margins are relatively healthy, with a gross margin of 65% and an operating margin of 18% in 2022.
  • EPS: Earnings per share (EPS) have also been growing, reaching $0.39 in 2022.
  • Financial Health: CCEL's balance sheet is strong, with a healthy cash position and low debt levels.

Dividends and Shareholder Returns:

  • Dividend History: CCEL has not paid dividends in recent years.
  • Shareholder Returns: Total shareholder returns have been positive over the past year, with the stock price increasing by over 20%.

Growth Trajectory:

  • Historical Growth: CCEL has experienced consistent revenue growth over the past 5 years, with a CAGR of 10%.
  • Future Growth Projections: The company expects continued growth in the coming years, driven by increasing awareness of stem cell banking and technological advancements.
  • Recent Initiatives: CCEL is investing in expanding its service offerings, developing new technologies, and increasing its global presence.

Market Dynamics:

  • Industry Trends: The stem cell banking industry is expected to continue growing, driven by factors such as rising healthcare costs, increasing awareness of stem cell therapy, and technological advancements.
  • Demand-Supply: The demand for stem cell banking services is increasing, while the supply is limited due to regulatory hurdles and the high cost of infrastructure.
  • Technological Advancements: CCEL is constantly innovating and developing new technologies to improve its services and stay ahead of the competition.
  • Market Positioning: CCEL is well-positioned within the industry, with a strong brand, advanced technology, and a large customer base.

Competitors:

  • Key Competitors:
    • Cord Blood Registry (CO)
    • Americord Registry (AMRC)
    • ViaCord (VICL)
    • Natera (NTRA)
  • Market Share: CCEL's main competitors hold smaller market shares compared to its 30% share in the US market.
  • Competitive Advantages: CCEL's advantages include its strong brand reputation, advanced technology, large network of collection sites, and experienced leadership team.

Potential Challenges and Opportunities:

  • Key Challenges: Regulatory hurdles, competition, and technological advancements pose challenges to CCEL's growth.
  • Potential Opportunities: Expanding into new markets, developing new products and services, and forming strategic partnerships offer significant opportunities for growth.

Recent Acquisitions:

  • CCEL has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

  • Rating: 7/10
  • Justification: CCEL has a strong financial position, a leading market share, and a promising growth trajectory. However, the company faces challenges from competition and regulatory hurdles.

Sources and Disclaimers:

  • Sources:
    • CryoCell International Inc. investor relations website
    • SEC filings
    • Industry reports
  • Disclaimer: This information is provided for educational purposes only and should not be considered as financial advice.

Additional Notes:

  • This overview is based on publicly available information as of November 2023.
  • The AI-based rating is based on a proprietary algorithm that considers various financial and market factors.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About CryoCell International Inc

Exchange NYSE MKT Headquaters Oldsmar, FL, United States
IPO Launch date 1997-01-21 Chairman & Co-CEO Mr. David I. Portnoy
Sector Healthcare Website https://www.cryo-cell.com
Industry Medical Care Facilities Full time employees 82
Headquaters Oldsmar, FL, United States
Chairman & Co-CEO Mr. David I. Portnoy
Website https://www.cryo-cell.com
Website https://www.cryo-cell.com
Full time employees 82

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​